Affinage

MARK1

Serine/threonine-protein kinase MARK1 · UniProt Q9P0L2

Length
795 aa
Mass
89.0 kDa
Annotated
2026-06-10
100 papers in source corpus 12 papers cited in narrative 12 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MARK1 (PAR-1C) is a serine/threonine kinase that controls microtubule dynamics, axonal transport, and neuronal polarity by phosphorylating microtubule-associated proteins (tau, MAP2, MAP4) at KXGS motifs within their repeat domains, detaching them from microtubules (PMID:12429843, PMID:15466480). This detachment converts microtubule tracks from a tau-blocked to a transport-competent state: MARK expression rescues motor-driven transport of mitochondria and APP vesicles that is otherwise inhibited by tau overload, without altering intrinsic motor velocity (PMID:15466480), and MARK-mediated tau phosphorylation is required for the microtubule plasticity that underlies neurite outgrowth and axon-dendrite specification (PMID:12429843, PMID:18492799). MARK1 activity is set by a layered regulatory network. Activation requires phosphorylation of the activation-loop threonine, performed by LKB1 in complex with STRAD and MO25 (raising activity >50-fold) and by the Ste20-family kinase MARKK/TAO-1; a second, inhibitory phosphorylation adjacent to the activating site tunes activity (PMID:14976552, PMID:14517247, PMID:19090997). The C-terminal KA1 domain enforces autoinhibition by binding the kinase domain, using the same residues that bind anionic phospholipids, so that engagement of membrane lipids relieves autoinhibition only when a second membrane-targeting signal is present (PMID:27879374). Death-associated protein kinase (DAPK) activates MARK1/2 non-catalytically, its death domain binding the MARK spacer to disrupt the intramolecular autoinhibitory interaction (PMID:21311567), whereas PAK5 inactivates MARK by binding the catalytic domain to block tau phosphorylation and stabilize microtubules (PMID:19090997, PMID:17047359). In epithelia, H. pylori CagA binds and inhibits MARK/PAR1 and shields it from aPKC-mediated phosphorylation that normally displaces it from the membrane, producing junctional and polarity defects (PMID:17507984). MARK1 has been identified as an autism spectrum disorder susceptibility gene, with both gain and loss of function shortening dendrites in cortical neurons (PMID:18492799).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2002 High

    Established the core substrate logic of MARK family kinases: how does phosphorylation of MAPs translate into control of neuronal morphology?

    Evidence Dominant-negative, pharmacological inhibition, and tau KXGS-motif mutagenesis with neurite outgrowth assays in N2a cells

    PMID:12429843

    Open questions at the time
    • Demonstrated for MARK2; isoform-specific contribution of MARK1 to KXGS phosphorylation not resolved here
    • Endogenous physiological tau pools versus overexpressed substrate not distinguished
  2. 2003 High

    Identified an upstream activating kinase and the activation-loop site, answering how MARK is switched on and revealing a dual-phosphorylation tuning mechanism.

    Evidence Co-IP, in vitro kinase assays, phosphorylation site mapping, dominant-negative constructs

    PMID:14517247

    Open questions at the time
    • Physiological stimulus driving MARKK/TAO-1 activity unknown
    • Identity of the kinase setting the inhibitory S212 phosphorylation not established
  3. 2004 High

    Defined a second activation-loop kinase, placing MARK within the LKB1/AMPK-related kinase hierarchy and establishing T-loop phosphorylation as the master activity switch.

    Evidence In vitro kinase assays, T-loop mutagenesis, activity measurement in LKB1-deficient cells

    PMID:14976552

    Open questions at the time
    • Whether LKB1 and MARKK act redundantly or in distinct contexts on MARK1 unresolved
    • Spatial/temporal control of LKB1 toward MARK1 not addressed
  4. 2004 High

    Connected MARK substrate phosphorylation to a concrete cellular output: relief of tau-mediated blockade of axonal transport.

    Evidence Live-cell imaging of mitochondria/APP vesicle transport in primary retinal ganglion neurons with MARK and tau co-expression

    PMID:15466480

    Open questions at the time
    • Endogenous MARK1 contribution under physiological tau levels not isolated
    • Selectivity among cargo adaptors not dissected
  5. 2007 High

    Revealed bacterial hijacking of MARK/PAR1 as a polarity effector, defining inhibitory binding and protection from aPKC as a disease-relevant regulatory axis.

    Evidence Reciprocal co-IP, kinase inhibition assays, polarity and junction readouts in epithelial cells

    PMID:17507984

    Open questions at the time
    • MARK1-specific versus pan-PAR1 contribution to the CagA phenotype not separated
    • Structural basis of CagA-MARK binding not defined here
  6. 2008 Medium

    Linked MARK1 to autism susceptibility and to dendritic morphology, establishing a dosage-sensitive neuronal role.

    Evidence Overexpression and siRNA in mouse neocortical neurons with dendrite morphometry and transport quantification

    PMID:18492799

    Open questions at the time
    • Mechanistic link between genetic association and dendrite phenotype not fully resolved
    • Single lab; causal variant function not reconstituted
  7. 2008 Medium

    Consolidated the multidomain regulatory architecture and identified PAK5 inhibition by direct catalytic-domain binding rather than phosphorylation.

    Evidence Structural analysis, co-IP, kinase and domain assays (review/summary)

    PMID:19090997

    Open questions at the time
    • Review consolidation; some mechanisms not original to this work
    • 14-3-3 targeting specificity for MARK1 not quantitatively defined
  8. 2011 High

    Defined DAPK as a non-catalytic activator that disrupts MARK autoinhibition, linking MARK activation to tauopathy-associated neurodegeneration.

    Evidence Death-domain/spacer co-IP, kinase assays, DAPK-/- mouse phospho-tau analysis, Drosophila PAR-1 epistasis

    PMID:21311567

    Open questions at the time
    • Structural detail of the death-domain/spacer interaction not resolved
    • Relative contribution of DAPK versus T-loop kinases in vivo unquantified
  9. 2016 High

    Established the KA1 domain as the autoinhibitory and membrane-sensing module, defining how anionic phospholipids relieve autoinhibition under a dual-signal requirement.

    Evidence In vitro kinase assays with isolated domains, KA1 mutagenesis, lipid vesicle activation assays

    PMID:27879374

    Open questions at the time
    • Identity of the required second membrane-targeting signal in cells unknown
    • Integration of KA1-lipid sensing with T-loop phosphorylation not reconstituted
  10. 2018 Medium

    Identified post-transcriptional control of MARK1 by miR-125a-5p and a role in tumor cell migration, extending MARK1 function beyond neurons.

    Evidence 3'-UTR luciferase reporter, MARK1 siRNA, transwell migration assays in cervical tumor cells

    PMID:29076440

    Open questions at the time
    • Downstream pathway linking MARK1 loss to migration not defined
    • Single lab; no in vivo validation
  11. 2016 Medium

    Framed MARK/PAR-1 within conserved cell-polarity logic, antagonizing anterior PAR proteins across organisms.

    Evidence Review consolidating genetic epistasis, localization, and kinase data across C. elegans, Drosophila, and mammals

    PMID:28236972

    Open questions at the time
    • Review; mammalian MARK1-specific polarity mechanisms generalized from orthologs
    • Direct substrates mediating polarity antagonism not enumerated here

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple inputs (LKB1/MARKK T-loop phosphorylation, DAPK autoinhibition release, KA1-lipid sensing, PAK5/CagA inhibition) are integrated spatially and temporally to set MARK1 activity at specific subcellular sites remains unresolved.
  • No unified model of competing activating and inhibitory inputs in a single cellular context
  • Endogenous MARK1-specific substrate repertoire beyond tau/MAP2/MAP4 not mapped
  • Structural basis for membrane-dependent activation in cells unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 4 GO:0016740 transferase activity 3 GO:0008092 cytoskeletal protein binding 2
Localization
GO:0005856 cytoskeleton 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3
Partners
14-3-3CAGADAPKLKB1MARKK/TAO1MO25PAK5STRAD

Evidence

Reading pass · 12 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 LKB1, in complex with STRAD and MO25, phosphorylates the T-loop threonine of MARK1 (and other AMPK-related kinases), increasing kinase activity >50-fold. Mutation of the T-loop Thr to Ala prevents activation; mutation to Glu produces constitutively active forms. Endogenous MARK1 activity is markedly reduced in LKB1-deficient cells. In vitro kinase assays, site-directed mutagenesis of T-loop residues, activity measurements in LKB1-deficient cells The EMBO journal High 14976552
2003 MARKK (a Ste20-family kinase, also called TAO-1) is an upstream activating kinase for MARK. MARKK phosphorylates MARK within its activation loop at T208 (in MARK2 numbering). A fraction of brain MARK is doubly phosphorylated at T208/S212; the second phosphorylation at S212 is inhibitory. MARKK activation of MARK enhances microtubule dynamics through phosphorylation and detachment of tau/MAPs from microtubules. Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mapping, cell transfection with overexpression and dominant-negative constructs The EMBO journal High 14517247
2007 H. pylori CagA specifically interacts with PAR1/MARK kinase. CagA association inhibits PAR1 kinase activity and prevents aPKC-mediated phosphorylation of PAR1 that normally dissociates PAR1 from the membrane, causing junctional and polarity defects. PAR1 also promotes CagA multimerization, stabilizing the CagA–SHP2 interaction. Induction of the hummingbird phenotype by CagA-activated SHP2 requires simultaneous inhibition of PAR1 kinase activity by CagA. Co-immunoprecipitation, kinase activity assays, dominant-negative and overexpression constructs, cell polarity and junction assays Nature High 17507984
2002 MARK2 (a MARK family member) phosphorylates tau at KXGS motifs in the repeat domain, causing detachment of tau from microtubules and their destabilization. Inactivation of MARK2 by dominant-negative mutant or inhibitors blocks neurite formation in N2a neuroblastoma cells. Rendering the KXGS motifs non-phosphorylatable by point mutations also blocks neurite formation, indicating that MARK-mediated tau phosphorylation is required for microtubule plasticity needed for neuronal polarity and neurite outgrowth. Dominant-negative transfection, pharmacological inhibition (hymenialdisine), point mutagenesis of tau KXGS motifs, neurite outgrowth assays Molecular biology of the cell High 12429843
2004 MARK/Par-1 phosphorylates MAPs (tau, MAP2, MAP4) at KXGS motifs, detaching them from microtubule tracks and thereby facilitating motor-driven vesicle transport. Expression of MARK rescues the transport inhibition of mitochondria, APP vesicles, and other cargoes caused by tau overload in primary retinal ganglion cells, without changing the intrinsic velocity of active motor movement. Live-cell imaging of vesicle/organelle transport, transfection of MARK and tau constructs in primary neurons and cell lines, quantification of transport parameters The Journal of cell biology High 15466480
2011 Death-associated protein kinase (DAPK) activates MARK1/2 through a direct interaction: the DAPK death domain (not its catalytic domain) binds to the MARK1/2 spacer region, disrupting an intramolecular autoinhibitory interaction within MARK1/2. This DAPK-mediated MARK activation leads to tau/MAP phosphorylation, microtubule destabilization, and modulation of neuronal polarity. In a Drosophila tauopathy model, DAPK acts partly through the MARK ortholog PAR-1 to induce neurodegeneration in a PAR-1 phosphorylation-dependent manner. Co-immunoprecipitation (DAPK death domain – MARK1/2 spacer), kinase activity assays, DAPK−/− mouse brain phospho-tau analysis, Drosophila genetic epistasis, neurite outgrowth assays Cell death and differentiation High 21311567
2016 The KA1 domain at the C-terminus of human MARK1 directly interacts with and inhibits the MARK1 kinase domain (autoinhibition). Residues in the KA1 domain required for autoinhibition are the same residues that mediate anionic phospholipid binding. A 'mini' MARK1 becomes activated upon association with anionic phospholipid-containing vesicles, but only when a second membrane-targeting signal is also present, indicating that dual membrane signals are required for relieving autoinhibition. In vitro kinase assays with isolated domains, site-directed mutagenesis of KA1 domain residues, lipid vesicle binding/activation assays, domain-deletion analysis The Biochemical journal High 27879374
2008 MARK family kinases contain multiple regulatory domains (kinase domain, UBA domain, spacer, KA1 domain) that mediate regulation through phosphorylation (activation loop phosphorylation by upstream kinases), protein–protein interactions (14-3-3 proteins, PAK5), and subcellular targeting. PAK5 inactivates MARK not by phosphorylation but by direct binding to the catalytic domain, thereby preventing tau phosphorylation and stabilizing microtubules. MARKK activates MARK by phosphorylating the activation loop threonine. MARK and its regulators mediate crosstalk between actin and microtubule cytoskeletons. Structural analysis (X-ray crystallography referenced for human MARKs), co-immunoprecipitation, kinase assays, domain analysis BMC neuroscience Medium 19090997
2008 MARK1 is identified as a susceptibility gene for autism spectrum disorders. Both overexpression and siRNA-mediated silencing of MARK1 result in significantly shorter dendrite length in mouse neocortical neurons, and MARK1 overexpression modifies dendritic transport speed, demonstrating MARK1's role in axon-dendrite specification and dendritic morphology. MARK1 overexpression and siRNA knockdown in mouse neocortical neurons, morphometric analysis of dendrite length, dendritic transport quantification Human molecular genetics Medium 18492799
2018 MARK1 is a direct functional target of miR-125a-5p. Luciferase reporter assays confirmed that miR-125a-5p directly binds a predicted target site in the MARK1 3'-UTR. siRNA-mediated knockdown of MARK1 in HeLa and C-33A cervical tumor cells stimulates cell migration, phenocopying the effect of miR-125a-5p overexpression. Luciferase reporter assay (3'-UTR), siRNA knockdown of MARK1, transwell migration assays, miRNA mimic transfection MicroRNA Medium 29076440
2006 MARK/Par-1 regulation involves multiple modes: activation loop phosphorylation by MARKK (activating), phosphorylation by aPKC (dissociating from membrane), interaction with 14-3-3 proteins (subcellular targeting/scaffolding), and inhibitory binding by PAK5 to the catalytic domain. PAK5 prevents MARK-induced tau phosphorylation, stabilizes microtubules, and contributes to actin dynamics via cofilin activation, establishing MARK and its regulators as mediators of cytoskeletal crosstalk. Co-immunoprecipitation, kinase activity assays, transfection/overexpression in cells, phosphorylation site analysis Neuro-degenerative diseases Medium 17047359
2016 PAR-1/MARK kinases localize and function in opposition to anterior PAR proteins to control asymmetric factor distribution in polarized cells. In mammalian neurons, MARK controls microtubule dynamics; in C. elegans zygote and Drosophila oocyte, PAR-1 (MARK ortholog) establishes anterior/posterior polarity through antagonistic interactions with anterior PAR proteins (including aPKC-mediated phosphorylation of PAR-1 that displaces it from the membrane). Review consolidating genetic epistasis, localization studies (live imaging, immunofluorescence), and kinase assays across multiple organisms Current topics in developmental biology Medium 28236972

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 The Polycomb complex PRC2 and its mark in life. Nature 2648 21248841
2006 Genomic DNA methylation: the mark and its mediators. Trends in biochemical sciences 1764 16403636
2012 Histone methylation: a dynamic mark in health, disease and inheritance. Nature reviews. Genetics 1734 22473383
2011 ER tubules mark sites of mitochondrial division. Science (New York, N.Y.) 1688 21885730
2004 LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. The EMBO journal 1157 14976552
2016 G-quadruplex structures mark human regulatory chromatin. Nature genetics 736 27618450
2011 First off the mark: early seed germination. Journal of experimental botany 436 21430292
2016 Protein prenylation: unique fats make their mark on biology. Nature reviews. Molecular cell biology 432 26790532
2019 The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature 414 31485078
2007 Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 404 17507984
2015 High IFN-γ and low SLPI mark severe asthma in mice and humans. The Journal of clinical investigation 332 26121748
2017 DNA methylation: an epigenetic mark of cellular memory. Experimental & molecular medicine 314 28450738
2006 Eisosomes mark static sites of endocytosis. Nature 293 16496001
2018 The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark. Wiley interdisciplinary reviews. RNA 276 30311405
2007 Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Current opinion in cell biology 273 17466503
2016 H3K27 methylation: a promiscuous repressive chromatin mark. Current opinion in genetics & development 243 27940208
2002 Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Molecular biology of the cell 215 12429843
2016 Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot. Cell metabolism 207 27076075
2004 MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. The Journal of cell biology 190 15466480
2018 Lysine benzoylation is a histone mark regulated by SIRT2. Nature communications 181 30154464
2009 The tau of MARK: a polarized view of the cytoskeleton. Trends in biochemical sciences 178 19559622
2021 The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes. Clinical epigenetics 176 34238359
2015 DNA N(6)-methyladenine: a new epigenetic mark in eukaryotes? Nature reviews. Molecular cell biology 167 26507168
2003 Targeting epidermal growth factor receptor--are we missing the mark? Lancet (London, England) 165 12853203
2003 MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. The EMBO journal 165 14517247
2021 Histone lactylation: epigenetic mark of glycolytic switch. Trends in genetics : TIG 156 34627643
2013 Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutation research 136 23927873
2004 Dynamic histone modifications mark sex chromosome inactivation and reactivation during mammalian spermatogenesis. Proceedings of the National Academy of Sciences of the United States of America 132 15536132
2010 Ubiquitin makes its mark on immune regulation. Immunity 126 21168777
2016 ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes. Molecular cell 124 27477906
2014 Cancer epigenetics drug discovery and development: the challenge of hitting the mark. The Journal of clinical investigation 115 24382391
2009 Histone acetylations mark origins of polycistronic transcription in Leishmania major. BMC genomics 115 19356248
2013 The chromatin response to DNA breaks: leaving a mark on genome integrity. Annual review of biochemistry 107 23414304
2003 Yeasts make their mark. Nature cell biology 99 12669083
2017 Post-translational add-ons mark the path in exosomal protein sorting. Cellular and molecular life sciences : CMLS 94 29080091
2016 N6-Methyladenine: A Conserved and Dynamic DNA Mark. Advances in experimental medicine and biology 91 27826841
2006 Clustered DNA motifs mark X chromosomes for repression by a dosage compensation complex. Nature 89 17122774
2004 An overview of the KIN1/PAR-1/MARK kinase family. Biology of the cell 86 15182702
2021 CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator. Trends in cell biology 84 33485722
2012 Delays and diversions mark the development of B cell responses to Borrelia burgdorferi infection. Journal of immunology (Baltimore, Md. : 1950) 82 22547698
2007 A site to remember: H3K36 methylation a mark for histone deacetylation. Mutation research 82 17346757
2009 Replication timing as an epigenetic mark. Epigenetics 81 19242104
2008 The MBD protein family-reading an epigenetic mark? Mutation research 81 18692077
2015 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. Biochimica et biophysica acta 80 25579174
2022 Plant DNA Methylation: An Epigenetic Mark in Development, Environmental Interactions, and Evolution. International journal of molecular sciences 78 35955429
2014 Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World journal of biological chemistry 76 24921003
2017 Making the Mark: The Role of Adenosine Modifications in the Life Cycle of RNA Viruses. Cell host & microbe 73 28618265
2011 DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity. Cell death and differentiation 73 21311567
2016 Enigmatic 5-hydroxymethyluracil: Oxidatively modified base, epigenetic mark or both? Mutation research. Reviews in mutation research 67 27036066
2009 Does chromatin remodeling mark systemic acquired resistance? Trends in plant science 67 19369112
2014 Role of the N6-methyladenosine RNA mark in gene regulation and its implications on development and disease. Briefings in functional genomics 66 25305461
2021 RNA 5-methylcytosine modification and its emerging role as an epitranscriptomic mark. RNA biology 65 34288807
2019 H3K4me2 functions as a repressive epigenetic mark in plants. Epigenetics & chromatin 64 31266517
2008 Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism. Human molecular genetics 63 18492799
2023 Menin "reads" H3K79me2 mark in a nucleosomal context. Science (New York, N.Y.) 62 36795828
2014 Hitting the 'mark': interpreting lysine methylation in the context of active transcription. Biochimica et biophysica acta 62 24631869
2012 5-Hydroxymethylcytosine--the elusive epigenetic mark in mammalian DNA. Chemical Society reviews 61 22842880
2016 PionX sites mark the X chromosome for dosage compensation. Nature 58 27580037
2011 Accessibility and evolutionary conservation mark bacterial small-rna target-binding regions. Journal of bacteriology 58 21278294
2007 The Par-1/MARK family of protein kinases: from polarity to metabolism. Cell cycle (Georgetown, Tex.) 58 17721078
2016 DNA methylation: a permissive mark in memory formation and maintenance. Learning & memory (Cold Spring Harbor, N.Y.) 56 27634149
2013 Cell-free expression--making a mark. Current opinion in structural biology 55 23628286
2008 Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC neuroscience 54 19090997
2010 Decoding the histone H4 lysine 20 methylation mark. Critical reviews in biochemistry and molecular biology 50 20735237
2020 DNA adenine methylation in eukaryotes: Enzymatic mark or a form of DNA damage? BioEssays : news and reviews in molecular, cellular and developmental biology 48 33244833
2011 Role of LKB1-SAD/MARK pathway in neuronal polarization. Developmental neurobiology 48 21416623
2021 G-quadruplexes mark alternative lengthening of telomeres. NAR cancer 46 34316718
2013 On your histone mark, SET, methylate! Epigenetics 46 23625014
2006 Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neuro-degenerative diseases 46 17047359
2019 Hdac3, Setdb1, and Kap1 mark H3K9me3/H3K14ac bivalent regions in young and aged liver. Aging cell 43 31858687
2014 Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation. The Journal of international medical research 42 24517927
2022 Bacterial N4-methylcytosine as an epigenetic mark in eukaryotic DNA. Nature communications 41 35228526
2020 PDGFRα and αSMA mark two distinct mesenchymal cell populations involved in parenchymal and vascular remodeling in pulmonary fibrosis. American journal of physiology. Lung cellular and molecular physiology 41 32023084
2016 Regulation of Cell Polarity by PAR-1/MARK Kinase. Current topics in developmental biology 41 28236972
2008 CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Molecular medicine (Cambridge, Mass.) 41 19052657
2019 Neurog3-Independent Methylation Is the Earliest Detectable Mark Distinguishing Pancreatic Progenitor Identity. Developmental cell 40 30620902
2015 H3K27me3 is an Epigenetic Mark of Relevance in Endometriosis. Reproductive sciences (Thousand Oaks, Calif.) 40 25820690
2019 Lgr5 and Col22a1 Mark Progenitor Cells in the Lineage toward Juvenile Articular Chondrocytes. Stem cell reports 39 31522976
2023 Linking chromatin acylation mark-defined proteome and genome in living cells. Cell 38 36868209
2018 Understanding the Histone DNA Repair Code: H4K20me2 Makes Its Mark. Molecular cancer research : MCR 37 29858375
2016 Cooperation between the H3K27me3 Chromatin Mark and Non-CG Methylation in Epigenetic Regulation. Plant physiology 37 27535791
2014 Pharmacodynamic biomarkers: falling short of the mark? Clinical cancer research : an official journal of the American Association for Cancer Research 37 24831281
2021 Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid. Nature communications 36 34545082
2017 Eomesodermin and T-bet mark developmentally distinct human natural killer cells. JCI insight 36 28289707
2012 Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax. Genome biology 36 23075511
2011 Epigenetics, development, and cancer: zebrafish make their mark. Birth defects research. Part C, Embryo today : reviews 35 21671358
2021 Nucleotide excision repair leaves a mark on chromatin: DNA damage detection in nucleosomes. Cellular and molecular life sciences : CMLS 34 34731255
2022 Microbial functional changes mark irreversible course of Tibetan grassland degradation. Nature communications 33 35562338
2024 Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung. JCI insight 32 39509324
2020 Detection methods of epitranscriptomic mark N6-methyladenosine. Essays in biochemistry 31 33284953
2015 N6-methyladenine functions as a potential epigenetic mark in eukaryotes. BioEssays : news and reviews in molecular, cellular and developmental biology 31 26293475
2020 A mark of disease: how mRNA modifications shape genetic and acquired pathologies. RNA (New York, N.Y.) 29 33376192
2014 Canonical and noncanonical roles of Par-1/MARK kinases in cell migration. International review of cell and molecular biology 29 25262242
2019 TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark. Biochemistry 27 31746185
2019 Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation. The Journal of investigative dermatology 26 31837302
2018 MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells. MicroRNA (Shariqah, United Arab Emirates) 26 29076440
2011 DNA hypermethylation as an epigenetic mark for oral cancer diagnosis. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 26 21649736
2008 MYSTs mark chromatin for chromosomal functions. Current opinion in cell biology 26 18511253
2021 Photoactivatable ribonucleosides mark base-specific RNA-binding sites. Nature communications 25 34654832
2016 Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase. The Biochemical journal 25 27879374

Missed literature

Know a paper Affinage missed for MARK1? Flag it for the maintainers and the community.

No submissions yet.